Lipdaune

Lovastatin, the active ingredient in Lipdaune, is a statin presented as an oral dosage form for oral use. It lowers elevated cholesterol levels and is prescribed for adults with hypercholesterolemia, familial hypercholesterolemia, or at risk of cardiovascular disease. The medication works by inhibiting hepatic cholesterol synthesis, helping to achieve target lipid profiles and reduce the likelihood of atherosclerotic events.

GNH USA supplies Lipdaune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide through reliable distribution networks.

Lovastatin is used to manage disorders of lipid metabolism and to reduce cardiovascular risk. - Hypercholesterolemia: lowers total and LDL cholesterol to target levels. - Familial hypercholesterolemia: reduces elevated LDL cholesterol in genetically predisposed patients. - Prevention of cardiovascular disease: helps decrease the incidence of heart attack and stroke in at‑risk individuals.

Lovastatin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Muscle aches or weakness - Headache - Gastrointestinal discomfort (nausea, abdominal pain, diarrhea) - Elevated liver enzymes

Serious or Rare Side Effects: - Rhabdomyolysis (severe muscle breakdown) - Acute liver injury or hepatitis - Severe allergic reactions (rash, angioedema, anaphylaxis)

Before initiating therapy with Lovastatin, consider the following precautions. - Pregnancy: contraindicated; classified Category X due to fetal risk. - Breastfeeding: not recommended; drug may pass into milk. - Liver disease: avoid in active hepatic impairment or unexplained persistent elevations of transaminases. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Store at below 25°C: keep in original container, protect from moisture and light.

Lovastatin interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, HIV protease inhibitors): can cause marked increase in Lovastatin levels. - Gemfibrozil or fenofibrate: heighten risk of myopathy and rhabdomyolysis. - Niacin (especially sustained‑release): increases muscle toxicity. - Bile‑acid sequestrants (e.g., cholestyramine): reduce Lovastatin absorption. - Antacids containing aluminum or magnesium: may lower bioavailability.

Moderate Interactions (Monitor Closely): - Amiodarone: may modestly raise Lovastatin concentrations. - Digoxin: potential for increased serum levels. - Warfarin: may enhance anticoagulant effect; monitor INR. - Macrolide antibiotics (e.g., erythromycin): may increase risk of muscle toxicity. - Grapefruit juice: can elevate Lovastatin exposure.